SCHEMBL6740552

SCHEMBL6740552

Cc1nc(C2=C(c3cc(F)c(S(C)(=O)=O)c(F)c3)COC2=O)cs1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 8/20 0.46
PTGS1 P23219 7/20 0.46
ALDH1A1 P00352 3/20 0.38
ABCB11 O95342 1/20 0.38
MT-CO2 P00403 1/20 0.38
HTR1A P08908 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
MC4R P32245 1/20 0.38
HTT P42858 1/20 0.37
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
USP2 O75604 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6733339 0.90 PTGS2 (0.41) PTGS2PTGS1ALDH1A1HTTHPGD
SCHEMBL6725412 0.86 PTGS2 (0.49) PTGS2PTGS1ALDH1A1ABCB11MT-CO2
SCHEMBL6733981 0.82 PTGS2 (0.46) PTGS2PTGS1ALDH1A1ABCB11MT-CO2
SCHEMBL6721681 0.81 PTGS2 (0.43) PTGS2PTGS1ALDH1A1HSD17B10SMN1; SMN2
SCHEMBL6733793 0.81 PTGS2 (0.50) PTGS2PTGS1ALDH1A1ABCB11MT-CO2
SCHEMBL6735522 0.81 PTGS2 (0.38) PTGS2PTGS1ALDH1A1ABCB11MT-CO2
SCHEMBL6733173 0.77 PTGS2 (0.56) PTGS2PTGS1ALDH1A1ABCB11MT-CO2
SCHEMBL6733528 0.77 PTGS2 (0.65) PTGS2PTGS1ALDH1A1ABCB11MT-CO2
SCHEMBL6734911 0.77 PTGS2 (0.62) PTGS2PTGS1ALDH1A1ABCB11MT-CO2
SCHEMBL6733737 0.76 PTGS2 (0.62) PTGS2PTGS1ALDH1A1ABCB11MT-CO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885PTGS1 4/4885ALDH1A1 434/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885PTGS1 4/4885ALDH1A1 434/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885PTGS1 4/4885ALDH1A1 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.